Institute for Medical Education and Research, Madelyn Trupkin Herzfeld, IMER, imer, imier, Miami, Florida, Nursing CE's, Nursing contact hours, nursing education, continuing education, medical research and education, Oncology, Postgraduate credit, oncology nurses, nurses, symposia, symposium, online educational credit, Breast Cancer, Cancer, cancer, breast cancer, colorectal cancer, Colorectal Cancer, Targeting EGFR, EGFR Inhibitors, egfr inhibitors, head and neck cancer, Anti-VEGF, VEGF Inhibitors, vegf inhibitors, lung cancer, head cancer, CINV, cinv, Chemotherapy Induced Nausea & Vomiting, chemotherapy, nausea, vomiting, mucositis, cancer pain, chronic pain  
Oncology Clinical Debates in Colorectal Cancer 2008
   
 

CME REGIONAL MEETINGS FOR ONCOLOGISTS

IMER Regional Meeting

New Options for Metastatic Breast Cancer

Target Audience

This activity has been designed to meet the educational needs of oncology physicians caring for patients with metastatic breast cancer.

Purpose

To review current treatment options and present novel treatment approaches for metastatic breast cancer.

Program Overview

It is estimated that more than 50,000 women will develop recurrent or metastatic breast cancer in 2008. Several paradigm shifts in treatment approaches have occurred in recent years as new therapeutic targets have been identified and agents developed to exploit them. This program will provide an overview of the current understanding of these targets and include a discussion of targets that remain under investigation. A breast oncology thought leader will discuss optimization of patient outcomes by integrating novel chemotherapeutic and biologic therapies into treatment. A list of ongoing and accruing clinical trials that may be options for your patients will also be outlined. Attendees are encouraged to bring challenging cases and questions for expert discussion. The program will conclude with a question-and-answer session.

 

Learning Objectives

Upon completion of this program, participants should be better able to:

  • Review current standards of care for metastatic breast cancer
  • Identify new and investigational therapies and their associated targets
  • Describe recent advances in the treatment of metastatic breast cancer
  • Identify significant ongoing/accruing clinical trials involving patients with metastatic breast cancer

Program Agenda

6:30 pm – 7:00 pm Registration
7:00 pm – 7:05 pm Program Overview
7:05 pm – 7:10 pm New Therapeutic Targets
7:10 pm – 7:25 pm New Options and New Agents: Integrating Novel Approaches to Optimize Patient Outcomes
7:25 pm – 7:35 pm Summary of Selected Ongoing/Accruing Clinical Trials: Expected Treatment Paradigm Shifts
7:35 pm – 8:00 pm Case Discussions/Questions & Answers

 

 

 

 

 

 

Jointly sponsored by:

IMER
Postgraduate Institute for Medicine

Additional CME Meetings on This Topic:

{date} {city} {speaker}

{icon}
{location}

Faculty

MEDICAL ONCOLOGISTS
Edith A. Perez, MD (Chairperson)
Mayo Clinic, Jacksonville
Aman U. Buzdar, MD
 The University of Texas M. D. Anderson Cancer Center
William J. Gradishar, MD, FACP
Northwestern University Feinberg School of Medicine
Joyce A. O’Shaughnessy, MD
US Oncology
Sandra M. Swain, MD
Washington Hospital Center
Virginia G. Kaklamani, MD
Northwestern University Feinberg School of Medicine
Edward H. Romond, MD
University of Kentucky
Hope S. Rugo, MD
University of California, San Francisco
Sridhar Mani, MD
Albert Einstein College of Medicine

 

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and IMER. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

PIM designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Conflicts of Interest

PIM assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

 

 

 

 
   

© Copyright 2003 – 2008 Institute For Medical Education & Research, Inc. All Rights Reserved.